You're signed outSign in or to get full access.
Ben Mee is a Research Associate specializing in equity research at Stephens, with a focus on the Diagnostics, Genomics, and Proteomics sectors. He covers companies within these fields, leveraging industry expertise gained from roles in Corporate Development and Investor Relations prior to rejoining Stephens. Mee began his career after graduating from the University of Wisconsin-Milwaukee with a B.B.A in Finance and a Certificate in Investment Management, and has since built a profile by providing in-depth company analysis and supporting key investor decisions. His credentials include academic training in finance and investment management, although there are no publicly listed FINRA registrations or securities licenses available for verification.
Ben Mee inquired about Cytek's willingness to be flexible on pricing in 2026 to facilitate instrument placements.
CEO Wenbin Jiang affirmed that Cytek's pricing strategy is market-driven. He emphasized that the company's competitive cost structure enables it to adapt to various market situations as necessary.
Fintool can predict 
CTKB's earnings beat/miss a week before the call
Ben Mee asked about Cytek's commercial investment plans for 2026, specifically if the company is comfortable with the current size of its sales teams and if there are particular areas targeted for investment in the coming year. Mee also inquired about Cytek's willingness to be flexible on pricing in 2026 to help drive instrument placements.
Wenbin Jiang, CEO, stated that Cytek focuses on the high-end market segment, represented by products like Aurora Evo and Aurora Cell Sorter, which saw double-digit growth. He indicated that the company is reviewing segments where it is weak and plans to continue investing in those areas to drive future revenue growth. Bill McCombe, CFO, added that investments have also been made in the reagent sales force, confirming that the commercial side remains a focus for investment. Jiang responded that Cytek's pricing is always market-driven and that the company's competitive cost structure allows it to adapt to any necessary situations.
Fintool can write a report on CTKB's next earnings in your company's style and formatting
Ben Mee from Stephens asked about the overlap between urologists targeted for Decipher in prostate cancer and those treating muscle-invasive bladder cancer (MIBC) who would be targets for Veracyte's MRD assay. He also inquired about the trend in ordering patterns for localized prostate cancer patients following the launch of the metastatic offering.
Chief Commercial Officer John Leite stated there is an exceptionally high overlap, expecting to serve upwards of 70% of the MIBC SAM through existing urologist and oncologist channels. CEO Marc Stapley explained that the metastatic launch added 30,000 addressable patients and helped drive growth across all risk categories for localized disease, with high-risk localized patients showing significant growth, partly influenced by metastatic data and NCCN guidelines.
Fintool can predict 
VCYT's earnings beat/miss a week before the call
Ben Mee inquired about the overlap of urologists who are Decipher targets for prostate cancer and also treat muscle-invasive bladder cancer (MIBC) for the upcoming MRD assay, and how Decipher's ordering patterns in localized high-risk patients have trended since the metastatic offering launch.
Chief Commercial Officer John Leite stated there is an exceptionally high overlap, expecting to serve over 70% of the MIBC market through existing urology and oncology channels. CEO Marc Stapley explained that the metastatic offering expanded Decipher's addressable market and has significantly driven growth in the high-risk localized patient segment, demonstrating strong traction across all prostate cancer risk categories.
Fintool can write a report on VCYT's next earnings in your company's style and formatting
